Loading...
Last submissions
-
Véronique Vendrely, Claire Lemanski, Pascal Pommier, Karine Le Malicot, Angélique Saint, et al.. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE. Radiotherapy & Oncology, 2023, 183, pp.109542. ⟨10.1016/j.radonc.2023.109542⟩. ⟨hal-04016479⟩
-
Diane Duroux, Héctor Climente-González, Lars Wienbrandt, Kristel Van Steen. Network Aggregation to Enhance Results Derived from Multiple Analytics. 16th IFIP International Conference on Artificial Intelligence Applications and Innovations (AIAI), Jun 2020, Neos Marmaras, Greece. pp.128-140, ⟨10.1007/978-3-030-49161-1_12⟩. ⟨hal-04050590⟩
-
-
-
-
-
-
-
-
-
-
Olivier Bylicki, Pascale Tomasini, Gervais Radj, Florian Guisier, Isabelle Monnet, et al.. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. European Journal of Cancer, 2023, 183, pp.38-48. ⟨10.1016/j.ejca.2023.01.014⟩. ⟨hal-04016683⟩
-
Serena Sirigu, James Hartman, Vicente José Planelles-Herrero, Virginie Ropars, Sheila Clancy, et al.. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113 (47), ⟨10.1073/pnas.1609342113⟩. ⟨hal-04041234⟩
-
-
-
-
-
-
-